| Date | Time | Source | Headline | Symbol | Company |
| 03/22/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | EU:IVA | Inventiva |
| 03/22/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | EU:IVA | Inventiva |
| 03/18/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
| 03/18/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2 | EU:IVA | Inventiva |
| 03/13/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
| 03/13/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | EU:IVA | Inventiva |
| 03/13/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 | EU:IVA | Inventiva |
| 03/07/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed | EU:IVA | Inventiva |
| 03/07/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed | EU:IVA | Inventiva |
| 03/07/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH | EU:IVA | Inventiva |
| 02/15/2024 | 4:35PM | GlobeNewswire Inc. | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | EU:IVA | Inventiva |
| 02/15/2024 | 4:35PM | GlobeNewswire Inc. | Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3 | EU:IVA | Inventiva |
| 02/15/2024 | 4:35PM | GlobeNewswire Inc. | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | EU:IVA | Inventiva |
| 01/24/2024 | 4:15PM | GlobeNewswire Inc. | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | EU:IVA | Inventiva |
| 01/24/2024 | 4:15PM | GlobeNewswire Inc. | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | EU:IVA | Inventiva |
| 01/24/2024 | 4:15PM | GlobeNewswire Inc. | Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux | EU:IVA | Inventiva |
| 01/10/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement | EU:IVA | Inventiva |
| 01/10/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | EU:IVA | Inventiva |
| 01/10/2024 | 4:00PM | GlobeNewswire Inc. | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | EU:IVA | Inventiva |
| 12/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program | EU:IVA | Inventiva |
| 12/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce la randomisation du premier patient en Chine dans l’étude clinique NATiV3 et fait le point sur son programme de développement clinique | EU:IVA | Inventiva |
| 12/20/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program | EU:IVA | Inventiva |
| 12/04/2023 | 4:05PM | GlobeNewswire Inc. | Inventiva annonce la recommandation positive du troisième DMC de l’étude clinique de Phase III avec lanifibranor dans la NASH | EU:IVA | Inventiva |
| 12/04/2023 | 4:05PM | GlobeNewswire Inc. | Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH | EU:IVA | Inventiva |
| 12/04/2023 | 4:05PM | GlobeNewswire Inc. | Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH | EU:IVA | Inventiva |
| 11/21/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva reports 2023 Third Quarter Financial Information¹ | EU:IVA | Inventiva |
| 11/21/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva publie ses informations financières du 3ème trimestre 2023¹ | EU:IVA | Inventiva |
| 11/21/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva reports 2023 Third Quarter Financial Information¹ | EU:IVA | Inventiva |
| 11/06/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD | EU:IVA | Inventiva |
| 11/06/2023 | 4:00PM | GlobeNewswire Inc. | Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 | EU:IVA | Inventiva |